SI1004582T1 - - Google Patents

Info

Publication number
SI1004582T1
SI1004582T1 SI9430476T SI9430476T SI1004582T1 SI 1004582 T1 SI1004582 T1 SI 1004582T1 SI 9430476 T SI9430476 T SI 9430476T SI 9430476 T SI9430476 T SI 9430476T SI 1004582 T1 SI1004582 T1 SI 1004582T1
Authority
SI
Slovenia
Prior art keywords
phenyl
deriv
substd
opt
furyl
Prior art date
Application number
SI9430476T
Other languages
English (en)
Inventor
Thomas Michael Bare
Timothy Wayne Davenport
James Roy Empfield
Kinney Jeffrey Alan Mc
Richard Bruce Sparks
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939321854A external-priority patent/GB9321854D0/en
Priority claimed from GB9417171A external-priority patent/GB9417171D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI1004582T1 publication Critical patent/SI1004582T1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SI9430476T 1993-10-22 1994-10-20 SI1004582T1 (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939321854A GB9321854D0 (en) 1993-10-22 1993-10-22 Pyridazino quinoline compounds
GB9417171A GB9417171D0 (en) 1994-08-25 1994-08-25 Pyridazino quinoline compounds
EP00101917A EP1004582B1 (en) 1993-10-22 1994-10-20 Pyridazino quinoline compounds

Publications (1)

Publication Number Publication Date
SI1004582T1 true SI1004582T1 (cs) 2005-08-31

Family

ID=26303731

Family Applications (2)

Application Number Title Priority Date Filing Date
SI9430314T SI0724583T1 (en) 1993-10-22 1994-10-20 Pyridazino quinoline compounds
SI9430476T SI1004582T1 (cs) 1993-10-22 1994-10-20

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI9430314T SI0724583T1 (en) 1993-10-22 1994-10-20 Pyridazino quinoline compounds

Country Status (29)

Country Link
US (3) US5744471A (cs)
EP (2) EP0724583B1 (cs)
JP (1) JP3583132B2 (cs)
KR (1) KR100261209B1 (cs)
CN (1) CN1053189C (cs)
AT (2) ATE198072T1 (cs)
AU (2) AU688393B2 (cs)
CA (1) CA2171332A1 (cs)
CZ (1) CZ292311B6 (cs)
DE (2) DE69434380T2 (cs)
DK (2) DK0724583T3 (cs)
ES (2) ES2154686T3 (cs)
FI (2) FI113865B (cs)
GB (1) GB9420590D0 (cs)
GR (1) GR3035080T3 (cs)
HU (1) HUT74161A (cs)
IL (1) IL111266A (cs)
MY (2) MY124316A (cs)
NO (1) NO306995B1 (cs)
NZ (2) NZ329303A (cs)
PL (1) PL180679B1 (cs)
PT (2) PT1004582E (cs)
RU (1) RU2168511C2 (cs)
SG (2) SG59971A1 (cs)
SI (2) SI0724583T1 (cs)
SK (1) SK282491B6 (cs)
TW (1) TW406082B (cs)
UA (1) UA60291C2 (cs)
WO (1) WO1995011244A1 (cs)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420590D0 (en) * 1993-10-22 1994-11-30 Zeneca Ltd Pyridazino quinoline compounds
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
US6214826B1 (en) 1994-11-12 2001-04-10 Zeneca Limited Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
US20050124622A1 (en) * 1999-12-23 2005-06-09 Brown Dean G. Compounds and methods for the treatment of pain
DE60026883T2 (de) * 1999-12-23 2006-11-23 Astrazeneca Ab Methoden und zusammensetzungen zur behandlung von schmerzen
US6943165B2 (en) * 1999-12-23 2005-09-13 Astrazeneca Ab Compound and method for the treatment of pain
EP1244664A1 (en) * 1999-12-23 2002-10-02 AstraZeneca AB Compounds and methods for the treatment of pain
WO2001047923A1 (en) * 1999-12-23 2001-07-05 Astrazeneca Ab Compounds and methods for the treatment of pain
US6787547B2 (en) 1999-12-23 2004-09-07 Astrazeneca Ab Compound and method for the treatment of pain
US6730675B2 (en) 1999-12-23 2004-05-04 Astrazeneca Ab Compounds and methods for the treatment of pain
HK1048767A1 (zh) * 1999-12-23 2003-04-17 阿斯特拉曾尼卡有限公司 治疗疼痛的方法和组合物
SI1244662T1 (cs) * 1999-12-23 2005-08-31 Astrazeneca Ab
SK8792002A3 (en) * 1999-12-23 2003-05-02 Astrazeneca Ab Quinoline-based compound, pharmaceutical composition containing same and use thereof
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
AU2420101A (en) * 1999-12-23 2001-07-09 Astrazeneca Ab Method and composition for the treatment of pain
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
JP2004509965A (ja) * 2000-09-29 2004-04-02 アストラゼネカ・アクチエボラーグ 1,2,5,10−テトラヒドロピリダジノ[4,5−b]キノリン−1,10−ジオン及び疼痛治療のためのその使用
ATE334982T1 (de) * 2000-09-29 2006-08-15 Astrazeneca Ab 7-chlor-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-
WO2002026738A1 (en) * 2000-09-29 2002-04-04 Astrazeneca Ab 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN
EP1325005A1 (en) * 2000-09-29 2003-07-09 AstraZeneca AB 1,2,5,10-tetrahydropyridazino 4,5-b]quinoline-1,10-diones and their use for the treatment of pain
HRP20031091B1 (en) * 2001-05-31 2012-05-31 Sanofi-Aventis Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
EP1655301B1 (en) * 2003-08-04 2015-03-11 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
MX2007000095A (es) * 2004-06-24 2007-03-21 Vertex Pharma Moduladores de transportadores con casete de union con atp.
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
JP2009521468A (ja) * 2005-12-24 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Abc輸送体の調節因子としてのキノリン−4−オン誘導体
BRPI0620960A2 (pt) 2005-12-28 2011-11-29 Vertex Pharmaceuticals Incorporated formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-didro-4- oxiquinolina-3- carboxamida
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
PL2821400T3 (pl) 2009-03-20 2018-04-30 Vertex Pharmaceuticals Incorporated Sposób wytwarzania modulatorów regulatora przewodności przezbłonowej zwłóknienia torbielowatego
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
IL311180A (en) 2012-02-27 2024-04-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
MX370450B (es) 2014-10-07 2019-12-13 Vertex Pharma Co-cristales de moduladores de regulador de conductancia de transmembrana en fibrosis quistica.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814458D0 (en) * 1988-06-17 1988-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
GB9109972D0 (en) * 1991-05-09 1991-07-03 Ici Plc Therapeutic compounds
GB9420590D0 (en) * 1993-10-22 1994-11-30 Zeneca Ltd Pyridazino quinoline compounds
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds

Also Published As

Publication number Publication date
AU7944094A (en) 1995-05-08
FI114916B (fi) 2005-01-31
PT1004582E (pt) 2005-09-30
TW406082B (en) 2000-09-21
MY124316A (en) 2006-06-30
SG92630A1 (en) 2002-11-19
UA60291C2 (uk) 2003-10-15
EP1004582A3 (en) 2000-08-30
DE69426422T2 (de) 2001-05-10
GB9420590D0 (en) 1994-11-30
SK50496A3 (en) 1997-03-05
CA2171332A1 (en) 1995-04-27
DE69434380D1 (de) 2005-06-23
FI961696A0 (fi) 1996-04-18
NO961584L (no) 1996-04-19
SI0724583T1 (en) 2001-04-30
MY132875A (en) 2007-10-31
NZ329303A (en) 2000-01-28
HK1013997A1 (en) 1999-09-17
FI961696L (fi) 1996-04-18
FI970907A0 (fi) 1997-03-03
CZ113896A3 (en) 1996-09-11
HU9600889D0 (en) 1996-06-28
NO961584D0 (no) 1996-04-19
SK282491B6 (sk) 2002-02-05
PL180679B1 (en) 2001-03-30
FI970907L (fi) 1997-03-03
US5744471A (en) 1998-04-28
JPH09504519A (ja) 1997-05-06
ES2154686T3 (es) 2001-04-16
EP0724583B1 (en) 2000-12-13
DE69426422D1 (de) 2001-01-18
EP0724583A1 (en) 1996-08-07
AU688393B2 (en) 1998-03-12
CZ292311B6 (cs) 2003-09-17
IL111266A0 (en) 1994-12-29
EP1004582B1 (en) 2005-05-18
ATE198072T1 (de) 2000-12-15
US6232313B1 (en) 2001-05-15
FI113865B (fi) 2004-06-30
DK0724583T3 (da) 2001-03-05
CN1053189C (zh) 2000-06-07
JP3583132B2 (ja) 2004-10-27
PT724583E (pt) 2001-03-30
SG59971A1 (en) 1999-02-22
NO306995B1 (no) 2000-01-24
GR3035080T3 (en) 2001-03-30
EP1004582A2 (en) 2000-05-31
US6103721A (en) 2000-08-15
WO1995011244A1 (en) 1995-04-27
RU2168511C2 (ru) 2001-06-10
DE69434380T2 (de) 2006-05-04
IL111266A (en) 2002-03-10
ATE295846T1 (de) 2005-06-15
AU6899998A (en) 1998-07-30
PL314041A1 (en) 1996-08-05
DK1004582T3 (da) 2005-08-15
AU721139B2 (en) 2000-06-22
NZ275472A (en) 1998-03-25
ES2241513T3 (es) 2005-11-01
HUT74161A (en) 1996-11-28
CN1138332A (zh) 1996-12-18
KR100261209B1 (ko) 2000-09-01

Similar Documents

Publication Publication Date Title
SI1004582T1 (cs)
PL328310A1 (en) Derivatives of quinazoline
MY129070A (en) Polishing composition and polishing method employing it
EA199900927A1 (ru) Трициклические соединения
ATE182891T1 (de) Indazolderivate
PT835659E (pt) Utilizacao de antagonistas nao petidicos da bradiquinina para a preparacao de medicamentos para o tratamento e prevencao da doenca de alzheimer
DE59206212D1 (de) Benzomorphane und ihre Verwendung als Arzneimittel
TW329424B (en) Derivatives of pentose monosaccharides and their uses for the treatment of an inflammatory or an autoimmune disorder
DE69207182D1 (en) Antitumor anthracenderivate
NZ515279A (en) Novel 8a- and 9a-15-membered lactams
DE69316392D1 (de) Azanoradamantane
ATE110367T1 (de) Kalziumantagonisten.
ZA928684B (en) Benzimidazole anthelmintic agents
FR2342063A2 (fr) Nouveaux acetamidoximes, leur procede de preparation et leur application en therapeutique